Cellectar Biosciences Inc (CLRB)
followers
·
Follow
Sector:
CONSUMER DISCRETIONARY
Industry:
CONSUMER SERVICES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
James V. Caruso
Employees:
10
100 CAMPUS DRIVE, FLORHAM PARK, NJ, 07932
(608) 441-8120
-
Formally known as:
- Cellectar Biosci
- CELLECTAR BIOSCIENCES INC COM STK
- Novelos Therapeutics, Inc.
- Novelos Therapeutics, Inc.
Date | Ratio |
---|---|
2011-04-11 | 1:153 |
2014-06-16 | 1:20 |
2016-03-07 | 1:10 |
2018-07-17 | 1:10 |
2022-07-22 | 1:10 |
Cellectar Biosciences, Inc. focuses on the discovery, development, and commercialization of drugs for cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies.
All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
---|